LIN Stock Analysis: Linde Ordinary Shares | NASDAQ
Specialty Chemicals | NASDAQ, USA | Market Cap: 244.947m USD | 12M Return: 13.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.23B
EPS Trend: 99.1%
Qual. Beats: 4
Rev. Trend: 81.2%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Linde plc is a global industrial gas company headquartered in Woking, United Kingdom, and founded in 1879. It produces and supplies atmospheric gases (oxygen, nitrogen, argon, and rare gases) as well as process gases such as hydrogen, helium, carbon dioxide, carbon monoxide, electronic gases, specialty gases, and acetylene. Beyond gas production, the company designs and builds turnkey process plants-including air separation, hydrogen, synthesis, olefin, and natural gas facilities-for both third-party customers and its own operations.
Its customer base spans healthcare, chemicals and energy, manufacturing, metals and mining, food and beverage, and electronics, with operations across the United States, Brazil, Mexico, Canada, Germany, the United Kingdom, Eastern Europe, China, Australia, South Korea, and India. As a member of the GICS Industrial Gases sub-industry, the industrial gases sector is generally characterized by high capital intensity, long-term contracts, and significant barriers to entry, with Linde being one of a small number of global producers alongside competitors such as Air Liquide and Air Products.
- Industrial gas volumes track global manufacturing PMI cycles
- Hydrogen clean energy project backlog drives new revenue growth
- Healthcare electronics specialty gas demand expands higher margin sales
| Net Income: 7.12b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.03 > 1.0 |
| NWC/Revenue: -7.62% < 20% (prev -2.69%; Δ -4.93% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.4b > Net Income 7.12b |
| Net Debt (23.4b) to EBITDA (13.3b): 1.77 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.3m) vs 12m ago -2.09% < -2% |
| Gross Margin: 45.99% > 18% (prev 36.93%; Δ 9.07% > 0.5%) |
| Asset Turnover: 41.01% > 50% (prev 39.92%; Δ 1.09% > 0%) |
| Interest Coverage Ratio: 34.52 > 6 (EBIT TTM 9.46b / Interest Expense TTM 274.0m) |
| A: -0.03 (Total Current Assets 12.8b - Total Current Liabilities 15.4b) / Total Assets 86.3b |
| B: 0.20 (Retained Earnings 17.6b / Total Assets 86.3b) |
| C: 0.11 (EBIT TTM 9.46b / Avg Total Assets 84.5b) |
| D: 0.83 (Book Value of Equity 38.6b / Total Liabilities 46.2b) |
| Altman-Z'' = 2.09 = BBB |
| DSRI: 1.03 (Receivables 5.64b/5.24b, Revenue 34.7b/33.0b) |
| GMI: 0.80 (GM 36.93% / 45.99%) |
| AQI: 0.99 (AQ_t 0.52 / AQ_t-1 0.52) |
| SGI: 1.05 (Revenue 34.7b / 33.0b) |
| TATA: -0.04 (NI 7.12b - CFO 10.4b) / TA 86.3b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of July 16, 2026, the stock is trading at USD 514.15 with a total of 1,466,402 shares traded. Over the past week, the price has changed by -2.56%, over one month by -1.41%, over three months by +3.58% and over the past year by +13.14%.
Current recommended Stop Loss: 498.30 (which is 3.1% or 1.4 ATR below the current price).
Linde Ordinary Shares has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy LIN.
- StrongBuy: 12
- Buy: 6
- Hold: 9
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 547.3 | 6.5% |
P/E Trailing = 35.0854
P/E Forward = 29.5858
P/S = 7.0682
P/B = 6.3514
P/EG = 2.2422
Revenue TTM = 34.7b USD
EBIT TTM = 9.46b USD
EBITDA TTM = 13.3b USD
Long Term Debt = 19.9b USD (from longTermDebt, last quarter)
Short Term Debt = 6.46b USD (from shortTermDebt, last quarter)
Debt = 27.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.08b
Net Debt = 23.4b USD (calculated: Debt 27.4b - CCE 3.96b)
Enterprise Value = 268b USD (245b + Debt 27.4b - CCE 3.96b)
Interest Coverage Ratio = 34.52 (Ebit TTM 9.46b / Interest Expense TTM 274.0m)
EV/FCF = 52.67x (Enterprise Value 268b / FCF TTM 5.10b)
FCF Yield = 1.90% (FCF TTM 5.10b / Enterprise Value 268b)
FCF Margin = 14.70% (FCF TTM 5.10b / Revenue TTM 34.7b)
Net Margin = 20.56% (Net Income TTM 7.12b / Revenue TTM 34.7b)
Gross Margin = 45.99% ((Revenue TTM 34.7b - Cost of Revenue TTM 18.7b) / Revenue TTM)
Gross Margin QoQ = 48.49% (prev 48.12%)
Tobins Q-Ratio = 3.11 (Enterprise Value 268b / Total Assets 86.3b)
Interest Expense / Debt = 1.00% (Interest Expense 274.0m / Debt 27.4b)
Taxrate = 21.95% (2.02b / 9.18b)
NOPAT = 7.38b (EBIT 9.46b * (1 - 21.95%))
Current Ratio = 0.83 (Total Current Assets 12.8b / Total Current Liabilities 15.4b)
Debt / Equity = 0.71 (Debt 27.4b / totalStockholderEquity, last quarter 38.6b)
Debt / EBITDA = 1.77 (Net Debt 23.4b / EBITDA 13.3b)
Debt / FCF = 4.60 (Net Debt 23.4b / FCF TTM 5.10b)
Total Stockholder Equity = 38.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.43% (Net Income 7.12b / Total Assets 86.3b)
RoE = 18.51% (Net Income TTM 7.12b / Total Stockholder Equity 38.5b)
RoCE = 16.21% (EBIT 9.46b / Capital Employed (Equity 38.5b + L.T.Debt 19.9b))
RoIC = 9.76% (NOPAT 7.38b / Invested Capital 75.6b)
WACC = 6.39% (E(245b)/V(272b) * Re(7.02%) + D(27.4b)/V(272b) * Rd(1.00%) * (1-Tc(0.22)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.97 | Cagr: -2.02%
[DCF] Terminal Value 75.93% ; FCFF base≈5.02b ; Y1≈5.20b ; Y5≈5.86b
[DCF] Fair Price = 145.1 (EV 90.5b - Net Debt 23.4b = Equity 67.1b / Shares 462.3m; r=8.35% [WACC [floored]]; 5y FCF grow 3.77% → 2.50% )
EPS Correlation: 99.05 | EPS CAGR: 8.47% | SUE: 3.01 | # QB: 4
Revenue Correlation: 81.18 | Revenue CAGR: 1.62% | SUE: 1.18 | # QB: 1
EPS current Quarter (2026-06-30): EPS=4.39 | Chg30d=N/A | Revisions=+25% | Analysts=19
EPS next Quarter (2026-09-30): EPS=4.61 | Chg30d=N/A | Revisions=+25% | Analysts=17
EPS current Year (2026-12-31): EPS=17.95 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+9.0% | GrowthRev=+7.7%
EPS next Year (2027-12-31): EPS=19.71 | Chg30d=N/A | Revisions=-17% | GrowthEPS=+9.8% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +10% (up=4, down=3)